Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349, SHA:688505) has enrolled the first patient in the confirmatory clinical trial of its aminolevulinic acid hydrochloride granules, a Thursday filing with the Hong Kong bourse said.
The product is being tested for the visualization of non-muscular invasive bladder cancer during the transurethral resection of the bladder tumor.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。